Agios Pharmaceuticals, Inc. (AGIO) EPS Estimated At $-1.65

February 14, 2018 - By Stephen Andrade

 Agios Pharmaceuticals, Inc. (AGIO) EPS Estimated At $ 1.65
Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.83, from 2.04 in 2017Q2. It fall, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported.
Ray Gerald L Assoc Ltd holds 0.25% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 29,465 shares. Pictet Asset invested in 0.01% or 54,700 shares. Ahl Ptnrs Limited Liability Partnership reported 6,971 shares. Clearbridge Investments Ltd Liability Corporation has invested 0.1% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Artal Group Incorporated Sa has 450,000 shares for 0.52% of their portfolio. Putnam Invests Limited Liability Corp invested in 0% or 15,623 shares. Swiss Bancorporation reported 0.01% stake. Moreover, Principal Fincl Gru Incorporated has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Us Bank De invested in 0% or 130 shares. Credit Suisse Ag reported 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Ameriprise Fincl reported 57,504 shares. Loomis Sayles And Co L P owns 211,598 shares or 0.03% of their US portfolio. Point72 Asset Mngmt L P owns 129,640 shares. Moreover, Macquarie Gru Limited has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Metropolitan Life holds 0% or 2,989 shares.

Since August 22, 2017, it had 0 buys, and 22 selling transactions for $25.02 million activity. $161,250 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was sold by Alenson Carman. Cantley Lewis Clayton Jr. also sold $227,400 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. On Monday, October 2 the insider Biller Scott sold $144,276. On Thursday, February 1 Bowden Christopher sold $157,500 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 2,000 shares. $1.87M worth of stock was sold by Hoerter Steven L. on Tuesday, January 23.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.65 EPS on February, 15.They anticipate $0.31 EPS change or 23.13 % from last quarter’s $-1.34 EPS. After having $-1.59 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see 3.77 % EPS growth. The stock decreased 0.52% or $0.4 during the last trading session, reaching $76.53. About 531,579 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since February 14, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Tuesday, August 8. Credit Suisse maintained the shares of AGIO in report on Thursday, November 2 with “Outperform” rating. JP Morgan upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, June 13 to “Overweight” rating. Oppenheimer maintained it with “Buy” rating and $7500 target in Sunday, June 11 report. The firm earned “Buy” rating on Wednesday, November 1 by RBC Capital Markets. The rating was upgraded by Leerink Swann to “Outperform” on Wednesday, August 2. The rating was maintained by Needham on Friday, September 15 with “Buy”. The rating was upgraded by Oppenheimer to “Outperform” on Tuesday, January 17. On Thursday, June 1 the stock rating was maintained by Oppenheimer with “Buy”. Credit Suisse maintained the stock with “Outperform” rating in Wednesday, May 18 report.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.26 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Globenewswire.com which released: “Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to …” on January 08, 2018, also Nasdaq.com with their article: “Agios Pharmaceuticals (AGIO) Q4 Earnings: What’s in Store?” published on February 09, 2018, Bostonglobe.com published: “Cambridge biotech Agios wins OK for its leukemia drug” on August 01, 2017. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Seekingalpha.com and their article: “Agios Pharmaceuticals: Updates To Thesis And A Look Toward 2018” published on December 14, 2017 as well as Seekingalpha.com‘s news article titled: “Agios Gears Up Pipeline To Create Future Value” with publication date: January 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.